Adenosine Receptors and Parkinson's Disease
- Hiroshi Kase, Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan
- Peter Richardson, University of Cambridge, U.K.
- Peter Jenner, King's College, London, U.K. Head of Pharmacology and Therapeutics Division
This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease. The effect of these novel non-dopamine drugs on vitro and in vivo systems clearly shows their potential for the treatment of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.
Neuroscientists, neurologists, pharmacologists, biochemists, and geneticists, especially all workers in the basal ganglia, purine, and Parkinson's fields.